CAMBRIDGE, Mass., Jan. 7, 2026 /PRNewswire/ -- STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced $8 million in Series Seed ...
CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been ...
BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects ...
BOSTON, Oct. 11, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
BOSTON, May 17, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics ...
BOSTON, July 24, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay Capital New Investment, Combined with Recent $8.4 Million ARPA-H Award, Brings Funds ...
BOSTON, Dec. 11, 2023 /PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results